A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen.

Trial Profile

A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Bendamustine (Primary) ; Brentuximab vedotin (Primary)
  • Indications Lymphatic disorders
  • Focus Therapeutic Use
  • Acronyms FIL-BBV
  • Most Recent Events

    • 02 Feb 2016 Status changed from not yet recruiting to recruiting as reported byClinicalTrials.gov.
    • 21 Jul 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top